Mr McCoy will continue to serve on the board as a director. Mr Edgerton has served on the company’s board of directors since February 2007.
Mr Edgerton spent two decades in a variety of positions for McKesson, a Fortune 15 healthcare services and information technology company.
CLX has recently closed its acquisition of ThyroTest, a rapid thyroid stimulating hormone screening device used for the detection of hypothyroidism in adults, a common thyroid disease. The company is currently implementing its ThyroTest marketing program and plans to select a national US distributor.
Mr Edgerton said: “I am pleased to fill the position of chairman of CLX Medical as the company begins to implement its strategy to market and distribute ThyroTest in the US and internationally. The management believes that this product has a tremendous future in the large potential testing market for hypothyroidism, and we look forward to executing the next steps, which are expected to include the naming of a US distributor and achieving the first new orders for the product.”